Advancing preclinical cancer models to assess clinically relevant outcomes

Anna Golebiewska; Ryan C. Fields

doi:10.1186/s12885-023-10715-7

Advancing preclinical cancer models to assess clinically relevant outcomes

Anna Golebiewska^*, Ryan C. Fields

^*Corresponding author for this work

NORLUX Neuro-Oncology Laboratory

Research output: Contribution to journal › Editorial

1 Citation (Scopus)

Abstract

Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer’s Collection of articles addressing ‘Advances in pre-clinical cancer models’ towards relivable outcomes at the preclinical stage.

Original language	English
Article number	230
Journal	BMC Cancer
Volume	23
Issue number	1
DOIs	https://doi.org/10.1186/s12885-023-10715-7
Publication status	Published - 10 Mar 2023

Access to Document

10.1186/s12885-023-10715-7Licence: CC BY

Cite this

@article{4d773fa2dee7460a8e9282aaa082551a,

title = "Advancing preclinical cancer models to assess clinically relevant outcomes",

abstract = "Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer{\textquoteright}s Collection of articles addressing {\textquoteleft}Advances in pre-clinical cancer models{\textquoteright} towards relivable outcomes at the preclinical stage.",

author = "Anna Golebiewska and Fields, {Ryan C.}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = mar,

day = "10",

doi = "10.1186/s12885-023-10715-7",

language = "English",

volume = "23",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Advancing preclinical cancer models to assess clinically relevant outcomes

AU - Golebiewska, Anna

AU - Fields, Ryan C.

PY - 2023/3/10

Y1 - 2023/3/10

N2 - Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer’s Collection of articles addressing ‘Advances in pre-clinical cancer models’ towards relivable outcomes at the preclinical stage.

AB - Cancer models are indispensable research tools for elucidating the mechanisms involved in tumor onset, progression and treatment resistance. They are key in evaluating therapeutics prior clinical trials. In this editorial, we invite contributions for a BMC Cancer’s Collection of articles addressing ‘Advances in pre-clinical cancer models’ towards relivable outcomes at the preclinical stage.

UR - http://www.scopus.com/inward/record.url?scp=85149923075&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/36899363

U2 - 10.1186/s12885-023-10715-7

DO - 10.1186/s12885-023-10715-7

M3 - Editorial

C2 - 36899363

AN - SCOPUS:85149923075

SN - 1471-2407

VL - 23

JO - BMC Cancer

JF - BMC Cancer

IS - 1

M1 - 230

ER -

Advancing preclinical cancer models to assess clinically relevant outcomes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this